Non-aids associated kaposi's sarcoma: Clinical features and treatment outcome

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Jakob, Lena ^a   Metzler, Gisela ^a   Chen, Ko Ming ^a   Garbe, Claus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; AZATHIOPRINE; CONSENSUS INTERFERON; CORTICOSTEROID; CORTICOSTEROID DERIVATIVE; CORTISONE ACETATE PLUS NEOMYCIN; CYCLOSPORIN A; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GEOGRAPHIC ORIGIN; GERIATRIC PATIENT; HUMAN; IATROGENIC DISEASE; IMMIGRANT; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LEG; MALE; MEDITERRANEAN SEA; NON AIDS ASSOCIATED KAPOSI SARCOMA; OBSERVATIONAL STUDY; ONSET AGE; RETROSPECTIVE STUDY; SEX RATIO; SKIN DEFECT; SOUTHERN EUROPE; SYSTEMIC THERAPY; TREATMENT RESPONSE; IMMUNOTHERAPY; PATHOLOGY; RADIOTHERAPY;

ADULT; AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MALE; RADIOTHERAPY; SARCOMA, KAPOSI;

EID: 79954539918     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018397     Document Type: Article

References (28)

1. Kaposi M, (1872) Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph 4: 265-272.
2. Antman K, Chang Y, (2000) Kaposi's sarcoma. N Engl J Med 342: 1027-1038.
3. Chang Y, Moore PS, (1996) Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS. Infect Agents Dis 5: 215-222.
4. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, et al. (2001) Biology of Kaposi's sarcoma. Eur J Cancer 37: 1251-1269.
5. Goh SG, Calonje E, (2008) Cutaneous vascular tumours: an update. Histopathology 52: 661-673.
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
7. Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R, (2000) Classic kaposi sarcoma: epidemiology and risk factors. Cancer 88: 500-517.
8. Dal ML, Polesel J, Ascoli V, Zambon P, Budroni M, et al. (2005) Classic Kaposi's sarcoma in Italy, 1985-1998. Br J Cancer 92: 188-193.
9. Ronchese F, Kern AB, (1953) Kaposi's sarcoma (angioreticulomatosis). Postgrad Med 14: 101-111.
10. Grulich AE, Beral V, Swerdlow AJ, (1992) Kaposi's sarcoma in England and Wales before the AIDS epidemic. Br J Cancer 66: 1135-1137.
11. Geddes M, Franceschi S, Barchielli A, Falcini F, Carli S, et al. (1994) Kaposi's sarcoma in Italy before and after the AIDS epidemic. Br J Cancer 69: 333-336.
12. Hoshaw RA, Schwartz RA, (1980) Kaposi's sarcoma after immunosuppressive therapy with prednisone. Arch Dermatol 116: 1280-1282.
13. Klepp O, Dahl O, Stenwig JT, (1978) Association of Kaposi's sarcoma and prior immunosuppressive therapy: a 5-year material of Kaposi's sarcoma in Norway. Cancer 42: 2626-2630.
14. Penn I, (1979) Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation 27: 8-11.
15. Royle JS, Baade P, Joske D, Fritschi L, (2010) Risk of second cancer after lymphohematopoietic neoplasm. Int J Cancer.
16. Hong A, Lee CS, (2002) Kaposi's sarcoma: clinico-pathological analysis of human immunodeficiency virus (HIV) and non-HIV associated cases. Pathol Oncol Res 8: 31-35.
17. Vogt T, Brockmeyer N, Kutzner H, Schofer H, (2008) Short German guidelines: angiosarcoma and Kaposi sarcoma. J Dtsch Dermatol Ges 6 (Suppl 1): S19-S24.
18. Trakatelli M, Katsanos G, Ulrich C, Kalabalikis D, Sotiriadis D, et al. (2010) Efforts to counteract locally the effects of systemic immunosupression: a review on the use of imiquimod, a topical immunostimulator in organ transplant recipients. Int J Immunopathol Pharmacol 23: 387-396.
19. Celestin Schartz NE, Chevret S, Paz C, Kerob D, Verola O, et al. (2008) Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 58: 585-591.
20. FDA (1998) KS drug goes to FDA. Food and Drug Administration. GMHC Treat Issues 12: 7.
21. Schwartz RA, Micali G, Nasca MR, Scuderi L, (2008) Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol 59: 179-206.
22. Szajerka T, Jablecki J, (2007) Kaposi's sarcoma revisited. AIDS Rev 9: 230-236.
23. Brambilla L, Bellinvia M, Tourlaki A, Scoppio B, Gaiani F, et al. (2010) Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol 162: 854-859.
24. Di LG, Kreuter A, Di TR, Guarini A, Romano C, et al. (2008) Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. J Invest Dermatol 128: 1578-1580.
25. Brambilla L, Romanelli A, Bellinvia M, Ferrucci S, Vinci M, et al. (2008) Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. Br J Dermatol 158: 1339-1344.
26. Montagnino G, Bencini PL, Tarantino A, Caputo R, Ponticelli C, (1994) Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report of 13 cases. Am J Nephrol 14: 121-126.
27. Sehgal SN, (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35: 7S-14S.
28. Stallone G, Schena A, Infante B, Di PS, Loverre A, et al. (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352: 1317-1323.